BioBeat

BioBeat operates in the remote patient monitoring (RPM) market, serving healthcare providers in hospitals, long-term care facilities, and pharmaceutical companies conducting clinical trials. Its business model revolves around providing a comprehensive platform that includes wearable monitoring devices and a cloud-based patient management system. The company generates revenue through the sale of its devices and likely through subscription access to its data platform and analytics. A key achievement for BioBeat was becoming the first company to receive FDA clearance for cuffless blood pressure monitoring using only a PPG sensor in 2019. Since then, it has secured further FDA clearances for a total of seven metrics, including blood oxygen saturation, pulse rate, respiratory rate, body temperature, stroke volume, and cardiac output.

The company offers two main wearable devices: a disposable short-term chest monitor and a reusable long-term wrist monitor. These devices continuously collect patient data, tracking up to 13 health parameters. The data is transmitted in real-time to a secure, HIPAA and GDPR compliant cloud platform. This platform features an AI-powered early warning score (EWS) system that analyzes the data to provide alerts on potential patient deterioration, enabling timely clinical intervention. For consumers, BioBeat has also introduced a direct-to-consumer, single-use chest patch kit for 24-hour blood pressure monitoring. The company has formed strategic partnerships, including an integration with Best Buy Health's Current Health platform to expand its reach in the care-at-home market.